Alberta Health Services
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 2009-04-01
- Employees
- 10K
- Market Cap
- -
Clinical Trials
42
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Prostate Cancer 18F-PSMA-1007 PET/CT Access Trial
- Conditions
- Prostate Cancer
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 1000
- Registration Number
- NCT06489496
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
- Conditions
- Neuroendocrine Tumors (NET)
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 500
- Registration Number
- NCT05673031
- Locations
- 🇨🇦
Foothills Medical Center 1403 29 St NW, Calgary, Alberta, Canada
The eCALM Study - An Online Mindfulness-Based Stress Reduction Program for Individuals Living With Cancer in Alberta
- Conditions
- Mindfulness-Based Stress Reduction (MBSR)Cancer
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 64
- Registration Number
- NCT01476891
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Frameless Stereotactic Radiosurgery for Brain Metastases
- Conditions
- Brain Metastases
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2011-11-22
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 20
- Registration Number
- NCT01476878
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Pharmacist Discharge Medication Reconciliation Study
- Conditions
- Medication Reconciliation
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 50
- Registration Number
- NCT01226589
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
Onco-Innovations Partners with University of Alberta to Advance PNKP Inhibitor Research for Glioblastoma Treatment
Onco-Innovations has entered into a research agreement with the University of Alberta and Cross Cancer Institute to expand preclinical studies of its PNKP inhibitor technology for hard-to-treat cancers, beginning with glioblastoma multiforme.
Breakthrough Gene Therapy Eliminates Need for Enzyme Replacement in Fabry Disease Patients
Canadian researchers have successfully developed a one-time gene therapy treatment for Fabry disease that restored enzyme production to near-normal levels in all five trial participants within one week.